DBV Technologies Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • DBV Technologies's estimated annual revenue is currently $1.6M per year.(i)
  • DBV Technologies's estimated revenue per employee is $6,094
  • DBV Technologies's current valuation is $185.3M. (January 2022}

Employee Data

  • DBV Technologies has 256 Employees.(i)
  • DBV Technologies grew their employee count by -31% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$32.9M212-10%N/AN/A
#2
$0.5M6-14%$10MN/A
#3
$4.3M31-9%$3.3MN/A
#4
$4.3M56143%$118MN/A
#5
$4.2M27-16%N/AN/A
#6
$0.7M9-18%$3.2MN/A
#7
$2.8M18100%N/AN/A
#8
$0.3M2N/AN/AN/A
#9
$3.6M2328%N/AN/A
#10
$7.8M50150%N/AN/A

DBV Technologies is a clinical-stage biopharmaceutical company developing treatments to help those with food allergies. With a new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of product candidates in Phase III, Phase II, and preclinical development. DBV is also pursuing a human proof-of-concept clinical study using their technology for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. Allergy, Food and pediatric allergy, Specific immunotherapy

keywords:N/A

N/A

Total Funding

256

Number of Employees

$1.6M

Revenue (est)

-31%

Employee Growth %

$185.3M

Valuation

N/A

Accelerator

DBV Technologies News

2022-04-17 - DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from ...

JMP Securities dropped their target price on shares of DBV Technologies from $8.00 to $5.00 and set a “market outperform” rating for the company...

2022-04-17 - DBV Technologies : AGM 2022 – Statutory auditors' report on the financial statements for the year ended December 31, 2021

DBV Technologies. Statutory auditors' report on the financial statements December 31, 2021. For the year ended December 31, 2021.

2022-04-17 - Ordinary and Extraordinary General Meeting of May 12, 2022

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company,...

2021-10-26 - DBV Technologies Reports Third Quarter 2021 Financial Results and Recent Regulatory Developments - Form 8-K

DBV Technologies Reports Third Quarter 2021 Financial Results and Recent Regulatory Developments DBV Technologies S.A. (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2021. T ...

2021-04-28 - DBV TECHNOLOGIES S.A. DBV Technologies S A : AGM 2021 – US Proxy Statement

DBV Technologies S.A. Proxy Statement for the 2021 Annual Combined General Meeting of Shareholders Dear Fellow Shareholders, DBV Technologies was founded on the belief that children with food allergies, their families, and the allergists who treat them, need and deserve multiple treatment op ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$62M25632%N/A
#2
$49.6M25643%$254.1M
#3
$80.3M25644%$156.7M
#4
$35.8M256156%$249.8M
#5
$38.5M25619%$223.1M